ZELBORAF is a prescription medicine used to treat: 1. a type of skin cancer called melanoma that: o has spread to other parts of the body or cannot be removed by surgery, and o has a certain type of abnormal “BRAF” gene. and 2. a type of blood cell cancer called Erdheim-Chester Disease (ECD) that: o can affect body tissues and organs, and o has a certain type of abnormal “BRAF” gene. Zelboraf (vemurafenib) was first approved August 17, 2011)

Where can I buy Zelboraf 240 mg Tablets?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. with over 20 years of domain experience.

The order for Zelboraf (vemurafenib) Tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

For Zelboraf or vemurafenib Tablets price in India. Please call at M: +91 9811747774 or Email Us to know more details about the medicine and its cost price in India.
ZELBORAF (vemurafenib)

Get In Touch

Facilitator under Patient Assistance Programs In India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Zelboraf (vemurafenib) on prescription and Import License in Patient's Name only.

For overseas patients, Zelboraf (vemurafenib) Tablets can be made available in Send your enquiry to find Zelboraf (vemurafenib) Tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

FDA News Release

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer.
Dated: November 6, 2017